The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020

• (g) in paragraph 26(1)(a)—

• (i) omit “or” at the end of subparagraph (iii);

• (ii) for “and” at the end of subparagraph (iv) substitute—

or (v) is deemed to hold a parallel import licence under paragraph 28(2); and

• (h) in paragraph 26(2), after “continues to apply to a person” insert “ where the UK marketing authorisation or parallel import licence authorises sale or supply of the medicinal product in Great Britain ”;

• (i) in paragraphs 27(1), 33(1), 45(1) and 50(1), after “offence relating to packaging and package leaflets” insert “ in Great Britain ”;

• (j) after paragraph 27 insert—

(27A) (1) This paragraph applies in relation to a parallel import licence granted by the licensing authority that was in force immediately before IP completion day. (2) A parallel import licence to which this paragraph applies— (a) has effect on and after IP completion day as a parallel import licence in force in the whole United Kingdom granted under regulation 49(1) of these Regulations; and (b) is treated as including a statement that it is in force in the whole United Kingdom for the purposes of regulation 49(1C).

• (k) in paragraph 28(2), after “granted under Part 5” insert “ , in force in Great Britain only, ”;

• (l) in paragraph 29, after sub-paragraph (7) insert—

(8) This paragraph, with the exception of sub-paragraphs (3) and (4), applies equally to a medicinal product imported into the United Kingdom pursuant to a parallel import licence and accordingly any reference in this paragraph (other than in this sub-paragraph) to— (a) a marketing authorisation or a UK marketing authorisation is to be read as a reference to a parallel import licence for a medicinal product, and (b) the holder of a UK marketing authorisation is to be read as a reference to the holder of a parallel import licence.

• (m) after paragraph 29 insert—

(29A) (1) Sub-paragraph (2) applies where— (a) an EU marketing authorisation was in force before IP completion day, (b) that authorisation is in force on IP completion day (whether or not it is suspended); and (c) that authorisation is for a medicinal product of a type that is specified in regulation 60B(2) (requirement to submit samples and other information to the appropriate authority). (2) Where this sub-paragraph applies, the EU marketing authorisation is deemed to be subject to the batch testing requirement in regulation 60B on and after IP completion day. (3) Sub-paragraph (4) applies where a holder of an EU marketing authorisation has, before IP completion day, submitted to a competent authority of an EEA State samples for testing from a batch of a medicinal product (“the relevant batch”) that— (a) is the subject of that authorisation; and (b) is of a type specified in regulation 60B(2). (4) Where this sub-paragraph applies, the holder of the EU marketing authorisation is deemed to have satisfied the batch testing requirement in regulation 60B in respect of the relevant batch if, before IP completion day— (a) the competent authority of that EEA State examines the sample from the relevant batch; and (b) that authority declared it to be in conformity with the approved specifications (within the meaning of Article 114 of the 2001 Directive) before IP completion day. (5) Sub-paragraphs (5) and (6) of paragraph 29 apply in relation to the appropriate authority's management of the list published under regulation 60A(5) for the purposes of this paragraph and regulation 60B.

• (n) in paragraph 41, in sub-paragraphs (3), (5) and (8)—

• (i) in paragraphs (a) and (b), omit “with which the United Kingdom concurred”;

• (ii) in paragraph (c), omit “, or where such an opinion has been given but the United Kingdom recorded a divergent opinion,”;

• (o) after paragraph 41 insert—

(41A) Where a relevant medicinal product is subject to a global marketing authorisation as described in Article 6 of the 2001 Directive before IP completion day, a paediatric investigation plan does not need to be carried out in relation to that product.

• (p) omit Part 7 (transitional provision in relation to orphan medicinal products);

• (q) in paragraph 44(2), after “continues to apply to a person” insert “ , in relation to a certificate of registration in force in Great Britain, ”;

• (r) in paragraph 49(2), after “continues to apply to a person” insert “ , only in relation to a registration in force in Great Britain, and ”;

• (s) in paragraph 52(1), after “traditional herbal registration” insert “ to be in force in Great Britain only ”;

• (t) in paragraph 53, after “traditional herbal registration” insert “ in force in Great Britain only ”;

• (u) in paragraph 55(1)(a), after “traditional herbal registration” insert “ to be in force in Great Britain only ”;

• (v) omit paragraph 56;

• (w) omit paragraph 57;

• (x) in paragraph 58—

• (i) in sub-paragraph (1)(a), after “specified matter” insert “ in relation to a UKMA(GB) or a THR(GB) ”;

• (ii) in sub-paragraph (2), for “UK marketing authorisation or traditional herbal registration” substitute “ UKMA(GB) or THR(GB) ”;

• (iii) in sub-paragraph (7)(a), after “specified matter” insert “ in relation to a UKMA(GB) or a THR(GB) ”;

• (y) in paragraph 59—

• (i) in sub-paragraph (1)(a), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (ii) in sub-paragraph (2)—

• (aa) for “revocation” substitute “ amendment ”;

• (bb) for “UK marketing authorisation or traditional herbal registration” substitute “ UKMA(GB) or THR(GB) ”;

• (iii) in sub-paragraph (3)(a), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (z) in paragraph 60—

• (i) in sub-paragraph (1)(b), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (ii) in sub-paragraph (2), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (iii) in sub-paragraph (3)(a), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (iv) in sub-paragraph (5)(a), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (aa) in paragraph 61—

• (i) in sub-paragraphs (2)(a) and (b), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (ii) in sub-paragraph (4), for “revocation” substitute “ amendment ”;

• (iii) in sub-paragraph (5)(b), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”;

• (iv) in sub-paragraph (6)—

• (aa) for “revocation” substitute “ amendment ”;

• (bb) in paragraph (b), after “holder” insert “ of a UKMA(GB) or a THR(GB) ”.

PART 23 — Amendment of Schedule 8 (consequential provision)

194

In Schedule 8 (consequential provision)—

• (a) in paragraph 4 (amendment of the Prescription Only Medicines (Human Use) Order 1997)—

• (i) for “In article 5(1)” substitute “ After article 5(1) ”; and

• (ii) for “insert “ UK ” before “marketing authorisation” ” substitute “insert—

(1A) In paragraph (1) “marketing authorisation” means— (a) in relation to medicinal products for sale or supply in Great Britain, a UKMA(GB) or UKMA(UK); (b) in relation to medicinal products for sale or supply in Northern Ireland, a UKMA(NI) or UKMA(UK), an EU marketing authorisation or a parallel import licence.

• (b) in paragraph 8 (amendment of the Blood Safety and Quality Regulations 2005)—

• (i) for “as if reference” substitute “ as if the reference ”;

• (ii) after “within the meaning of” insert “ paragraph (a) of the definition of that term in ”;

• (c) for paragraph 7 (amendment of the Unlicensed Medicinal Products for Human Use (Transmissible Spongiform Encephalopathies) (Safety) Regulations 2003) substitute—

(7) In regulation 1(2) of the Unlicensed Medicinal Products for Human Use (Transmissible Spongiform Encephalopathies) (Safety) Regulations 2003 (citation, commencement and interpretation), for the definition of “unlicensed product” substitute— “unlicensed product” means— (a) in the case of a product to be imported or marketed in Great Britain, a medicinal product for human use, other than an excluded medicine, in respect of which no UKMA(GB), UKMA(UK), THR(UK) or THR(GB) has been granted; (b) in the case of a product to be imported or marketed in Northern Ireland, a medicinal product for human use, other than an excluded medicine, in respect of which no UKMA(NI), UKMA(UK), THR(UK) or THR(NI), EU marketing authorisation or Article 126a authorisation has been granted, and “Article 126a authorisation”, “EU marketing authorisation”, “THR(GB)”, “THR(NI)”, “THR(UK)”, “UKMA(GB)”, “UKMA(NI)” and “UKMA(UK)” have the meanings given in regulation 8 of the 2012 Regulations;.;

• (d) in paragraph 16 (amendment of the Branded Health Service Medicines (Costs) Regulations 2018)—

• (i) omit sub-paragraph (2)(a) to (d);

• (ii) omit sub-paragraph (3);

• (iii) omit sub-paragraph (4)(a)(i);

• (iv) for sub-paragraph (4)(a)(ii) substitute—

(ii) in sub-paragraph (b), after “Article 21” insert “ or regulation 64(6) of the 2012 Regulations ”; and

• (v) omit sub-paragraph (4)(b);

• (vi) omit sub-paragraph (5);

• (vii) omit sub-paragraph (6).

PART 24 — Amendment of Schedule 9 (retained EU law: revocations)

195

In Schedule 9 (retained EU law: revocations), in paragraph 1, after sub-paragraph (ii) insert—

(jj) Regulation (EU) 2019/5 of the European Parliament and of the Council of 11 December 2018 amending Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, Regulation (EC) No 1901/2006 on medicinal products for paediatric use and Directive 2001/83/EC on the Community code relating to medicinal products for human use.

SCHEDULE 3 — Amendment of the Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019

Amendment of the Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019

1

In Schedule 1—

• (a) omit paragraphs 2 to 6;

• (b) omit paragraph 8;

• (c) in paragraph 10, omit sub-paragraphs (3) and (4).

Signed

Signed by authority of the Secretary of State for Health and Social Care

Edward Argar — Minister of State, — 2020-12-03

We consent

Maggie Throup — Rebecca Harris — Two of the Lords Commissioners of Her Majesty's Treasury — 2020-12-08

Explanatory note

(This note is not part of the Regulations)

Footnotes

[^f00001]: 2018 c.16. Section 8C was inserted by section 21 of the European Union (Withdrawal Agreement) Act 2020 (c.1) and paragraph 21 of Schedule 7 was amended by paragraph 53(2) of Schedule 5 to that Act.

[^f00002]: S.I. 1999/3106.

[^f00003]: S.I. 2019/744.

[^f00004]: S.I. 2019/775.

[^f00005]: S.I. 2019/1385.

[^f00006]: S.I. 2003/431 (N.I. 9); article 11 is amended by S.R. 2009 No. 114.

[^f00007]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^f00008]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^f00009]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^f00010]: 2012 c.7.

[^f00011]: S.I. 2002/2013, as amended by S.I. 2012/1809 and prospectively amended with effect from IP completion day by S.I. 2019/87.

[^f00012]: 1968 c.67, as amended by section 26 of the Health Act 2006 (c.28) and S.I. 1971/1445, 1994/2987, 2006/2407, 2011/2581 and 2012/1916, and in relation to Scotland by paragraph 5 of Schedule 3 to the Regulation of Care (Scotland) Act 2001 (asp 8).

[^f00013]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^f00014]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^f00015]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^f00016]: 2006 c.46.

[^f00017]: S.I. 2003/1680. The definition of “unlicensed product” in regulation 1(2) was amended by S.I. 2004/3224, 2005/2750 and 2012/1916.

Editorial notes

[^c24373781]: 2018 c.16. Section 8C was inserted by section 21 of the European Union (Withdrawal Agreement) Act 2020 (c.1) and paragraph 21 of Schedule 7 was amended by paragraph 53(2) of Schedule 5 to that Act.

[^c24373791]: S.I. 1999/3106.

[^c24373801]: S.I. 2019/744.

[^c24373811]: S.I. 2019/775.

[^c24373821]: S.I. 2019/1385.

[^c24373831]: S.I. 2003/431 (N.I. 9); article 11 is amended by S.R. 2009 No. 114.

[^c24373841]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c24373851]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c24373861]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c24373871]: 2012 c.7.

[^c24373881]: S.I. 2002/2013, as amended by S.I. 2012/1809 and prospectively amended with effect from IP completion day by S.I. 2019/87.

[^c24373891]: 1968 c.67, as amended by section 26 of the Health Act 2006 (c.28) and S.I. 1971/1445, 1994/2987, 2006/2407, 2011/2581 and 2012/1916, and in relation to Scotland by paragraph 5 of Schedule 3 to the Regulation of Care (Scotland) Act 2001 (asp 8).

[^c24373901]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c24373911]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c24373921]: The guidelines are available at: https://www.gov.uk/guidance/eu-guidance-documents-referred-to-in-the-human-medicines-regulations-2012 and a hard copy may be obtained from the Medicines and Healthcare products Regulatory Agency at the address given in the Explanatory Note.

[^c24373931]: 2006 c.46.

[^c24373941]: S.I. 2003/1680. The definition of “unlicensed product” in regulation 1(2) was amended by S.I. 2004/3224, 2005/2750 and 2012/1916.

[^key-c59412e3887a11e1b8b7398d834f0be0]: Reg. 1 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e730b4b793ddda90105bfdeda2c7dcc6]: Reg. 2 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-38407571671fb34329d5b6ed5d76b484]: Reg. 3 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-cb8a4f28a963a7ae37d5e17037f4f525]: Reg. 4 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e802dce69813ec4ac87e9b007f38f9af]: Reg. 5 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1c0247c872bd59dfa63414f94c8f3e17]: Sch. 1 para. 1 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9ab1bf45d4bb25ea31eaea96babb2e4f]: Sch. 1 para. 2 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-edd5815f2f8b9ca30bef278679bf5f28]: Sch. 1 para. 3 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-cb457cb5b36a803a3387236e1d154180]: Sch. 1 para. 4 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-62951987dfe896024a1dc36c62260eff]: Sch. 1 para. 5 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e3536450bbab4f84792e94218fea93af]: Sch. 1 para. 6 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-69782e6889b7be8c8cb467c4a3916c7f]: Sch. 1 para. 7 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-266d53133ee3b80b2a14ad258e870826]: Sch. 1 para. 8 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6271053d21c1c1d69ea2dffc8651fb25]: Sch. 1 para. 9 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-01bc041ad5f5d76ee5ef9711348e45c0]: Sch. 1 para. 10 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-b2000b97863cdc46116c1acd8970c9c6]: Sch. 2 para. 1 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ae10482e189e9a72ba9b983d18c0e87a]: Sch. 2 para. 2 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-075be8dae5b9a2599f4a682a4cfc69e8]: Sch. 2 para. 3 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-44d265d18cf59e1a80db45ba85a7ffbc]: Sch. 2 para. 4 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-08ba4e25a9897c8eb2ab5752dc0cda6d]: Sch. 2 para. 5 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-04625744c80c5848329e78575635c33e]: Sch. 2 para. 6 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-04d874ef502913aeebcd1e720d64346a]: Sch. 2 para. 7 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6022a3eda5f5f2211b0d123ff824d765]: Sch. 2 para. 8 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-64c47184f00dc044170a8d3fecda749b]: Sch. 2 para. 9 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4aecc0d12e37ab25892dbf5a338bfca2]: Sch. 2 para. 10 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e585c9bb2ed8f7b355d1e28d4296fd8d]: Sch. 2 para. 11 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-bfb9169badc748f3143a0597cb50119b]: Sch. 2 para. 12 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7f8284a342a83376ba77130ae41ee5c3]: Sch. 2 para. 13 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-5ed4ec1f190cac7e78ed9f5028ec8cb4]: Sch. 2 para. 14 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9d1f301259fb4bc3e07d6bc2f2d451e1]: Sch. 2 para. 15 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-0c63298988563da6a477d846d7390551]: Sch. 2 para. 16 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d1745dc98199379bd1d5bf9c7e520a11]: Sch. 2 para. 17 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-a9f50240a4caada7542a750bf017f5c6]: Sch. 2 para. 18 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-14bba573793b50f17ef3ea21f6cca4f8]: Sch. 2 para. 19 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-5187e30d0cb70663f64bef3cd3fe9c54]: Sch. 2 para. 20 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e89eab84871b309ec78c4e857909d5de]: Sch. 2 para. 21 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-c534f75382732bf2949cf72994362258]: Sch. 2 para. 22 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d82cc4bf15edc1c1f29f96727039d6d9]: Sch. 2 para. 23 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-bc0fa86f8ada125d519b0b833dba537a]: Sch. 2 para. 24 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e7abf24f39e5ad973c9f4a269509649d]: Sch. 2 para. 25 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-86103c5333bf38d571895ed9478dac4f]: Sch. 2 para. 26 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-661cf877d5e7785c12e273895bd8cc74]: Sch. 2 para. 27 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8eddb5c2956b82ded131c56b25a63d42]: Sch. 2 para. 28 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1b9555f86c7457e17c23dac7ba8f95af]: Sch. 2 para. 29 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-266e42f1753ccad3e6fa85680de10bc0]: Sch. 2 para. 30 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-68086afd9fe2792516c83744ba34a9ac]: Sch. 2 para. 31 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-35e49cb07996905ba65dc2e25c0df8ba]: Sch. 2 para. 32 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-a471e9cdd4edefb3798a1ff6d6443494]: Sch. 2 para. 33 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-2d07083559bb129e342396fe53390b28]: Sch. 2 para. 34 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-05a3cfdaf0a071cbbe70cf1de08a0726]: Sch. 2 para. 35 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-924b9f0d143ecff5e847d6679471c425]: Sch. 2 para. 36 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-38154075b9bb42e110e1daf310f40ae2]: Sch. 2 para. 37 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7530fb4621aaf038a948e90094d94fea]: Sch. 2 para. 38 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7e0bd7314606bd734b7d93a4195d99f1]: Sch. 2 para. 39 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8bbe8530db382e4d77cec58750156346]: Sch. 2 para. 40 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8ddb0d9db44735e8464894aeadf864ba]: Sch. 2 para. 41 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-bbb442f82c90994ab84f9337135311c1]: Sch. 2 para. 42 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9f8f6ab1749f392a684741ae770badf8]: Sch. 2 para. 43 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-a06e631faa7d9b0e819f4f9f41b11a44]: Sch. 2 para. 44 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-bbf6679cbc8384008cdad26b2b38f7eb]: Sch. 2 para. 45 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-328612314eea81efcb72b841e1aba2e4]: Sch. 2 para. 46 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9b39a469fc7d9be33494d4f0be3eee49]: Sch. 2 para. 47 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-63868e23803d73f20b712d113b84ddf8]: Sch. 2 para. 48 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4199f4a5a165ef5e7afd45374fe24b1d]: Sch. 2 para. 49 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6a15fc076e7d0de4071c45e5a166ac31]: Sch. 2 para. 50 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9ab56f7e7270d94df717fd77f52c5f8b]: Sch. 2 para. 51 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4494a3a7013f09e5cc1c6996bf0fe68f]: Sch. 2 para. 52 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-fe0ac23527be6c9e257e16bb028f1fdc]: Sch. 2 para. 53 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9b67a89937db89be06d1d67bbeb5675c]: Sch. 2 para. 54 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-cef29d90e283fef0db3e4d00831e5a97]: Sch. 2 para. 55 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7d648fedfde8367483243d4a2aa588c7]: Sch. 2 para. 56 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-b944eb7c4d71ff144d7e858eba5b5459]: Sch. 2 para. 57 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e3ae3333e809bcde8c0450325a8b5db3]: Sch. 2 para. 58 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7cbaa4709e11edae050d0281d7411c1f]: Sch. 2 para. 59 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6a46ac9b44b7f141c3ce838b8a3c2def]: Sch. 2 para. 60 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-029634fe4f3071826e97f8ba85dff73d]: Sch. 2 para. 61 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-36c97370cb4e3b9a6be08de43573120d]: Sch. 2 para. 62 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d33c240050872d36656e76c43cd35655]: Sch. 2 para. 63 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-676f0e834ebdcc673a3f7e953e6b45af]: Sch. 2 para. 64 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-a87a8ea4b60eaa2b2914684a58dbf8d6]: Sch. 2 para. 65 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-93d5a93f428101b32dfb7a73689ce451]: Sch. 2 para. 66 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-580f0a5d70a70299acc5c92f9d2a89f9]: Sch. 2 para. 67 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-002689e9e1de58b72ba70fe52097c225]: Sch. 2 para. 68 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-0913ba826457517dcd383e089f0274c0]: Sch. 2 para. 69 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8b422e3502b08c34ec6b38770120722d]: Sch. 2 para. 70 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-5a0d0607ee634d3da55aecf69bdc8100]: Sch. 2 para. 71 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1dd5f54c20543d1fafbcdf02764556b7]: Sch. 2 para. 72 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-faddc9af647a8e864d009d8d17082871]: Sch. 2 para. 73 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-27b9a10e32da42958cdc3b287f1c060d]: Sch. 2 para. 74 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-78396669174fd648a52794b098b06813]: Sch. 2 para. 75 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d9ac157f9b34fc371956e9fc57d96561]: Sch. 2 para. 76 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-631e33daaae42e0d798a51f12bf6665c]: Sch. 2 para. 77 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-05b0bfd09227ff270dfc32bbd39fea3b]: Sch. 2 para. 78 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-482099bd164be2dd4f05a81599f3ce3d]: Sch. 2 para. 79 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7d6a0014427559d53600ee038cfaa835]: Sch. 2 para. 80 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-f55c161e9c573aae955ecc17e90ef281]: Sch. 2 para. 81 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ed698eaf40645165da03de7fa6ddf7d7]: Sch. 2 para. 82 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8056ec22bd69f7adc081e718f02bbebd]: Sch. 2 para. 83 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-b4a6346ad31e73e9632c0ba17f11065f]: Sch. 2 para. 84 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-27ff3257345f59ad5060296a34d616be]: Sch. 2 para. 85 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6f752e1e11ac832432a7f09f18289eaa]: Sch. 2 para. 86 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-09a517e855f52bd036432f83e41e121f]: Sch. 2 para. 87 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-18d9caf38f0d9bd2ef9de7ded661b5a7]: Sch. 2 para. 88 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-62dbbec92cbae371cb546811b8cbbf54]: Sch. 2 para. 89 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-295a2620a10711a70de1890531e0e9b4]: Sch. 2 para. 90 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-afa727d5e0732a3b9ba9b520dbd423f1]: Sch. 2 para. 91 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-bf81d65c7676977f66b6af11e9122c58]: Sch. 2 para. 92 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d465b2b35ef6745016164619d6020a8f]: Sch. 2 para. 93 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ad7521858c9ef0d2bbefca1087710fec]: Sch. 2 para. 94 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1f162b5d45f34519f17348aebc64e578]: Sch. 2 para. 95 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-f370323b4e8a1a4f491b8b8f8ad565e9]: Sch. 2 para. 96 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-378a2868cb7e3faac78a0d0be299764b]: Sch. 2 para. 97 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e97679d2dac0aec5570eef93db8a72e1]: Sch. 2 para. 98 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-386c867fcdb1f6da09c21d2bd2829ab2]: Sch. 2 para. 99 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1082462daf4e4dab9e6f732db5c739a7]: Sch. 2 para. 100 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-c7c2a705202c2a316b3c081a9f8ab13a]: Sch. 2 para. 101 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-434f04e7e393157de0649d5d182f6276]: Sch. 2 para. 102 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-57c5111edc12875d143d16338dcb477d]: Sch. 2 para. 103 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-f18e38ce1aa5e2717d5c1f1026cde44a]: Sch. 2 para. 104 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ca04b28a2a1159061f1ae095f84f39d1]: Sch. 2 para. 105 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4473fe63f0d99941d9c2654b1cc01d16]: Sch. 2 para. 106 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ed43772ed1e5ac33ea59f62ce8e3ca69]: Sch. 2 para. 107 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e3e070fb178f8df84ff224f6f5e2f2c7]: Sch. 2 para. 108 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d90b5eb006fb1f5e1b2d01bf2504d204]: Sch. 2 para. 109 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-5aaf82740b0b2f932640800bb77b344d]: Sch. 2 para. 110 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ab8c6ed76e41c61579fb027ac3296118]: Sch. 2 para. 111 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ea9c3ded9c822d10194a63b8fcb686b5]: Sch. 2 para. 112 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-2e99404c956d75c9424e5fa2f4d66c90]: Sch. 2 para. 113 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-65033b685e882eb9709484163518fdce]: Sch. 2 para. 114 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-a206688b4518e95305686d77a2bcd109]: Sch. 2 para. 115 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-186d2f3b2a15672ba7122e71db9929ad]: Sch. 2 para. 116 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ce5587827567c0d30a9100849036ed1c]: Sch. 2 para. 117 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-cca2fe0618b7453a5f34fad4596785b7]: Sch. 2 para. 118 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-bb460966edfd238e27214901e89e551f]: Sch. 2 para. 119 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-91c55be237ab1770d3d854aefaa69f2d]: Sch. 2 para. 120 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-474a850598363db657defd1b03cae0e3]: Sch. 2 para. 121 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-871274343e3846bc87136953de54cf0a]: Sch. 2 para. 122 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-3ee9264aaa3f97141bef59eb87bdf0ce]: Sch. 2 para. 123 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-139512f4fce5ad838f36cdef6bb2a25a]: Sch. 2 para. 124 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-3f73bba66d672cc164108168224ca2f9]: Sch. 2 para. 125 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-492151c5a07e2c7682f72bb2c15e10ef]: Sch. 2 para. 126 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7a87afa334894240f5acd20f17009074]: Sch. 2 para. 127 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-55ebd9df5d5ebee1181e834d82459f91]: Sch. 2 para. 128 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1ea0e7ab14a00b51505b90cf107896c6]: Sch. 2 para. 129 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6e4c5363c963c3f5458b5a08773be656]: Sch. 2 para. 130 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4289f65cd2779330fb9d806c66734716]: Sch. 2 para. 131 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-7384d0e235c6c9142c38d59d453fcba4]: Sch. 2 para. 132 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-3d05ee1279221026da06ce96f1989e38]: Sch. 2 para. 133 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-51d6aaeadcb39ebe6c503f2ee8205f1a]: Sch. 2 para. 134 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-c05e1ea6daa7c0163ebe65cb718beb4e]: Sch. 2 para. 135 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-5aeac8482743fde8782a7d02c332cd54]: Sch. 2 para. 136 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-db0628adc268074aea05f999746c9de6]: Sch. 2 para. 137 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-b10f00813159c877a734d4f661cc607d]: Sch. 2 para. 138 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-fab3c892e824b5c3b1838f0c8f878a30]: Sch. 2 para. 139 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-5fe405a2997fac241061e772c23c6b5c]: Sch. 2 para. 140 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8f2f0155df98d6fae1871edd84180d33]: Sch. 2 para. 141 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8f9fc53cff3b0b88641c88cac118cb4c]: Sch. 2 para. 142 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4a4027f9de093546af13b86e7f17a44d]: Sch. 2 para. 143 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8d737a74817835b761b9eb56f5190e2c]: Sch. 2 para. 144 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-99da3f8c42c06c2583b083f1ee0e2c9a]: Sch. 2 para. 145 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-67884e5590b34c1c70b474736f62bb40]: Sch. 2 para. 146 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e3bb2ad6cea4af24119ac5bc6a67d433]: Sch. 2 para. 147 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1b3d8c9dbfdcc63e3305eb7633b480e7]: Sch. 2 para. 148 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4ca516c105810a14c4653a95d3bcbe10]: Sch. 2 para. 149 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-a8f288d1360ae516c08250a44ed55a27]: Sch. 2 para. 150 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-717e5300aaa13cfe026a104ddaa4fee2]: Sch. 2 para. 151 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4650feb69dbd49dd263e53eee9288824]: Sch. 2 para. 152 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-a19d6fd24f73309bf6ca0409f17e90a5]: Sch. 2 para. 153 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-f0f3a93c59d11ebd573f53212e81c08f]: Sch. 2 para. 154 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-b894347cc6a501a7296b51508eecfa4d]: Sch. 2 para. 155 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-ec6422b9748402d93e1882f091bd6df0]: Sch. 2 para. 156 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-90552241d71eef832e1b4befac251725]: Sch. 2 para. 157 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-3b9337f9f8a8234c18fe5d1a08affe36]: Sch. 2 para. 158 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-31650463b342299907517c43e428a732]: Sch. 2 para. 159 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4d5cf67cc7d97aea1f2d0f4944485930]: Sch. 2 para. 160 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e84fc99edd46ec765ab360e35364cb2d]: Sch. 2 para. 161 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d449b0bb7979ef4e1e9e794eca0ef933]: Sch. 2 para. 162 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-c86f197542679153a38e50929adfe0d8]: Sch. 2 para. 163 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-c3fe492ae8eed929016680590564aa16]: Sch. 2 para. 164 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-b0a0963049134ff1be5c142834a8717c]: Sch. 2 para. 165 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9cf4ee81b364fef2dc426d2b26589314]: Sch. 2 para. 166 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-df292985aae3abeefe88659c25065717]: Sch. 2 para. 167 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-57efe4e6091900957233baa1d14c1dcd]: Sch. 2 para. 168 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-d94d9ad47b318d95297262ce4858cf90]: Sch. 2 para. 169 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-c56b904e63a16b6d57570d8f7191c645]: Sch. 2 para. 170 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6eebd02235a4d3748d49ec850a8a3ae2]: Sch. 2 para. 171 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-8f8945f10e0c5bfb9c8a1960c6ca99ff]: Sch. 2 para. 172 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-f6dd951831da2f5643cef1dd9b6b7d6f]: Sch. 2 para. 173 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-971dc7e583476356e6bbc830f30c79fd]: Sch. 2 para. 174 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-879118b28c81ab6043372d673fc7abdb]: Sch. 2 para. 175 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-0d37057102824f5eb7245150bf175d79]: Sch. 2 para. 176 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-fd4d7c0f1a1c52a822a46922ed113374]: Sch. 2 para. 177 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-019defe3de6bd2c70444199a24490c69]: Sch. 2 para. 178 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1e88279ea701139a6632920098a612cf]: Sch. 2 para. 179 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-6d2f92cc72f4dd9f4815ffd685a35201]: Sch. 2 para. 180 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-f3150da258e0f1d5549825947d82bf4b]: Sch. 2 para. 181 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-1711109b949a1f9da59389914c940710]: Sch. 2 para. 182 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-797e75967717b6f7b4664de445dd279d]: Sch. 2 para. 183 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-84b213cd6e32de9ff260aed101ba6582]: Sch. 2 para. 184 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-4b641a840b58488c929aad30db851b58]: Sch. 2 para. 185 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-34e0130119c7ca0495af2238c8284909]: Sch. 2 para. 186 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-b36fd6fd38c316b4314a760d64049eae]: Sch. 2 para. 187 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-2e258f40fb8ad5825ac521c44d0c58aa]: Sch. 2 para. 188 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-93f6a27d8d51d152a5d6d5a594a7e928]: Sch. 2 para. 189 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-9690a8512ad4c2d68ba8ebf01094977f]: Sch. 2 para. 190 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-10ee2a33a7d1683899bc6640786337a5]: Sch. 2 para. 191 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-e4ee96680fdb66abfd488537a165e478]: Sch. 2 para. 192 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-316c4d56432086618aede81948a82bec]: Sch. 2 para. 193 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-09899c6f5be46457026a061ccbd921f2]: Sch. 2 para. 194 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-595b08542a39c6ab798c1006f5760776]: Sch. 2 para. 195 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-670e1c1f8ba88ced502812047b06fc52]: Sch. 3 para. 1 in force at 31.12.2020 immediately before IP completion day, see reg. 1

[^key-14d29c14e59d88749210de42e3d87f6b]: Sch. 2 para. 2(b) omitted (3.8.2021) by virtue of The Human Medicines (Amendment) (EU Exit) Regulations 2021 (S.I. 2021/834), regs. 1(2), 4